How much revenue does OncoSec Medical make?

OncoSec Medical reported $0 in revenue for fiscal year 2022. In Q2 2023 revenue was $0.

What companies are similar to OncoSec Medical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Notable Labs, Ltd. (NTBLQ), Cardax, Inc. (CDXI), Stem Holdings, Inc. (STMH), Mymetics Corporation (MYMX).

OncoSec Medical Incorporated (ONCSQ) Stock

About OncoSec Medical Incorporated

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which ...

At a glance

OncoSec Medical reported revenue of $0 for fiscal year 2022, and net income of -$34.18 million. In Q2 2023 (the quarter ended January 31, 2023) revenue was $0.

Figures from company filings; latest fiscal year ended July 31, 2022.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.